Anteris Technologies announces to raise AU$35 million via placement

Anteris Technologies Limited (ASX: AVR) announced that it has raised AU$35 million by issuing 1.458 million new ordinary shares to various sophisticated and professional investors at a price of AU$24.00 per share. The placement was led by the company's two largest holders, Perceptive Advisors and L1 Capital, both subscribed beyond their existing pro-rata shareholdings.

The funds raised from the placement will primarily be used for the clinical development of DurAVRTM, a 3D single-piece aortic valve used to treat aortic stenosis, as well as for general working capital purposes. Participants in the placement will receive one unlisted option to purchase an ordinary share in Anteris, which will expire two years from the date of issue and have an exercise price of AU$29.00.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com